GENINCODE PLC LS -01 - Asset Resilience Ratio
GENINCODE PLC LS -01 (9PL) has an Asset Resilience Ratio of 1.54% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how financially flexible is GENINCODE PLC LS -01 to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how GENINCODE PLC LS -01's Asset Resilience Ratio has changed over time. See GENINCODE PLC LS -01 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down GENINCODE PLC LS -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of GENINCODE PLC LS -01.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €65.00K | 1.54% |
| Total Liquid Assets | €65.00K | 1.54% |
Asset Resilience Insights
- Limited Liquidity: GENINCODE PLC LS -01 maintains only 1.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GENINCODE PLC LS -01 Industry Peers by Asset Resilience Ratio
Compare GENINCODE PLC LS -01's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for GENINCODE PLC LS -01 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for GENINCODE PLC LS -01.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.07% | €55.00K ≈ $64.30K |
€2.66 Million ≈ $3.11 Million |
+1.06pp |
| 2023-12-31 | 1.00% | €42.00K ≈ $49.10K |
€4.19 Million ≈ $4.89 Million |
+0.87pp |
| 2022-12-31 | 0.14% | €16.00K ≈ $18.71K |
€11.80 Million ≈ $13.79 Million |
+0.11pp |
| 2021-12-31 | 0.03% | €4.00K ≈ $4.68K |
€15.21 Million ≈ $17.78 Million |
-- |
About GENINCODE PLC LS -01
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to prov… Read more